Discover and read the best of Twitter Threads about #ACC2020
Most recents (2)
1/
⭐️How do we manage CAD in advanced CKD?
In this #Tweetorial, @BUMedicine classmates/future coresidents @RahulAggarwalMD and I review:
🔷#ISCHEMIA-CKD @NEJM #ACC2020
By @SripalBangalore @nyulangone & et al!
#MedTwitter #CardioTwitter #MedEd #COVID19 @MedTweetorials
⭐️How do we manage CAD in advanced CKD?
In this #Tweetorial, @BUMedicine classmates/future coresidents @RahulAggarwalMD and I review:
🔷#ISCHEMIA-CKD @NEJM #ACC2020
By @SripalBangalore @nyulangone & et al!
#MedTwitter #CardioTwitter #MedEd #COVID19 @MedTweetorials
2/
First off, a refresher pop-quiz on the #ISCHEMIA (Outcomes) trial @NEJM we summarized in last week's #Tweetorial!
Q: Patients with stable CAD and moderate/severe ischemia have better outcomes with which intervention?
First off, a refresher pop-quiz on the #ISCHEMIA (Outcomes) trial @NEJM we summarized in last week's #Tweetorial!
Q: Patients with stable CAD and moderate/severe ischemia have better outcomes with which intervention?
3/
If you missed our #Tweetorial last week, here is the link to review our summary of the #ISCHEMIA Outcomes main trial results:
If you missed our #Tweetorial last week, here is the link to review our summary of the #ISCHEMIA Outcomes main trial results:
I know that for you and the world, your primary focus is the CoVid pandemic and that is entirely right. #ACC2020 is currently ongoing and if you will forgive me, I will run a thread on the results of one of the late-breakers.
The trial I'm going to discuss is the SPYRAL PIVOTAL OFF MED trial of renal denervation, which has just been released as a late-breaker.
Renal Denervation? That doesn’t work does it?! Well, since 2014, that has been the mountain to climb. Symplicity HTN-3 was negative. Why was that?
